Bladder Cancer
If it’s your first time on this website, please read the disclaimer section.
Oct 05 – Oct 12, 2026
Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: A Nonrandomized Clinical Trial.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This phase 2 trial evaluated the efficacy and safety of disitamab vedotin combined with tislelizumab in 28 patients with transurethrally unresectable, ERBB2-positive, very high-risk non-muscle-invasive bladder cancer. A complete response was achieved in 73.1% (19/26) of evaluable patients, with a 24-month sustained response rate of 83.5% among responders. The study directly addresses the clinician’s interest in cancer by investigating a novel antibody-drug conjugate and immunotherapy combination for a difficult-to-treat oncological population. These findings suggest a potent nonsurgical alternative for patients ineligible for radical cystectomy, warranting further validation in randomized clinical trials.
10.1001/jamaoncol.2026.3909
Sep 28 – Oct 05, 2026
Urine cell-free RNA for bladder cancer detection and treatment response prediction.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This study evaluated uRARE-seq, a novel liquid biopsy method for profiling urine cell-free RNA (cfRNA), across 683 samples to detect and characterize bladder cancer. The method demonstrated 95% sensitivity and 90% specificity for localized bladder cancer detection, outperforming traditional urine tumor DNA analysis. Analysis successfully identified minimal residual disease and predicted BCG treatment response versus chemotherapy with an area under the curve of 0.93 based on immune and proliferation signatures. These findings suggest urine cfRNA is a highly effective non-invasive tool for cancer diagnosis and personalized treatment selection, pending prospective clinical validation.
10.1038/s41591-026-04673-3
Jul 27 – Aug 03, 2026
Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This single-arm, phase 3 trial (BOND-003 Cohort C) investigated intravesical cretostimogene grenadenorepvec oncolytic immunotherapy for high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ in 112 patients. After a median 25.8-month follow-up, 75% (83 of 110 patients; 95% CI 66.3-83.2) achieved a complete response, with adverse events being predominantly low-grade (e.g., bladder spasm 25%), and no grade 3/4 events or discontinuations. This research directly addresses a significant unmet need in cancer care by providing a potential bladder-sparing treatment for a challenging bladder cancer subtype. Cretostimogene demonstrates clinically meaningful anti-tumor activity and a favorable safety profile, positioning it as a promising innovative option for high-risk, BCG-unresponsive non-muscle-invasive bladder cancer.
10.1016/S1470-2045(26)00194-4